Better Mental Health
for More People
We are at a crisis point
in mental health provision.
Mental health and addiction (including alcohol), is the 5th leading cause of illness globally, affecting 20% of the world’s population.
Unlike other medical disciplines, psychiatry focuses on maintenance rather than cure, and symptom suppression rather than addressing the root causes of these illnesses.
The exception is Psychedelics and Psychedelic-Assisted Psychotherapy which have the potential to radically change mental health services and deliver significantly better patient outcomes.
Awakn Life Sciences is a biotechnology company with clinical operations researching, developing, and delivering psychedelic new chemical entity drugs and therapies to treat Addiction.
We are integrating psychedelic medicine into mainstream healthcare to enable better mental health for more people through Research, Digital, Clinics, and Ecosystems.
We have a dual strategic focus, to develop and commercialise proprietary psychedelic new chemical entity drugs and therapies to treat Addiction and to treat Addiction and other mental health conditions in a chain of medical psychedelic clinics across the UK and EU.
Our goals are to be the leader in biotech research of psychedelic new chemical entity drugs and therapies to treat Addiction, build, own, and operate the UK and EU’s leading chain of medical psychedelic clinics, and scale our reach through our Partnerships Ecosystem.
Clear IP development pathway
• New chemical entity drugs
• Clinical trials
• Advanced predictive analytics
Multiple revenue streams:
• Clinic revenue starting in 2021.
• Partnership Ecosystem revenue starting in 2022.
• Research revenue in 2026+.
First mover advantage in UK and EU:
400m people and CAD$25trn GDP.
Global research leaders in the field of psychedelic treatments for Addiction:
Dr. Ben Sessa led the world’s only MDMA-Assisted Psychotherapy and AUD study (BIMA) and Prof. Celia Morgan led the world’s only Ketamine-Assisted Psychotherapy AUD study (KARE).
The leading scientific and medical team in the industry:
Prof. David Nutt, Dr. Ben Sessa, Prof. Celia Morgan,, Dr. Michael Mithoefer, Ann Mithoefer, and Prof. Matt Johnson.
Strategic partnerships with two leading UK universities
for exclusive access to data and findings from recent clinics trials.
Our business consists of three related and complementary divisions: Research, Digital, Clinics, and Ecosystems.
Our team has led the research that has defined the psychedelic medicine industry, including: the Bristol Imperial MDMA for Alcoholism (BIMA) study and the Ketamine for Reduction of Alcoholic Relapse (KARE).
We have a portfolio of drug development and clinical trials planned and initiated focused on treating addiction.
Predictive Analytics to improve the efficiency of Psychedelic-Assisted Psychotherapy.
We provide hope for those whom the status quo is not working by combining the proven therapeutic potential of ketamine with psychotherapy to treat Addiction, Anxiety, Depression, and PTSD.
• Bristol Q1 2021
• London 1 & Manchester 2021
• London 2, Birmingham, Dublin (Ireland) 2022
• Continental Europe 2023+
Awakn Partnerships Ecosystems
Scale our reach beyond our core territories through licencing to enable addiction treatment practitioners deliver the Awakn methodology:
• Protocols & Therapy
• Clinic Design Best Practice
• Data, Analytics, Insights
Scientific Advisory Board
Our pioneering team is made up of some of the leading clinical researchers, scientific minds and clinical experts in the global industry